SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Xenon shares plunge after lead drug trial setback

Xenon said it submitted late Thursday, but the lead drug trial outcome is described as a clinical setback and the stock is reported to be having its worst day since 2017.

XENEAAUCHOOD

HEADLINESXenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged SwordWhat should have been a milestone for Xenon Pharmaceuticals was quickly derailed by a clinical setback-one that could prove a windfall for a similarly pressured rival.Xenon said late Thursday that it had submitt…

Related stories